Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carbone

Showing results (631-640 of 651) with videos related to

Pageof 66
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLCCeline Mascaux, Triparna Sen, Montse Sanchez-Cespedes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Medicine|October 10, 2023
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Cancer Medicine|July 28, 2025
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based TherapiesMingjia Li, Po-Lan Su, Songzhu Zhao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 26, 2025
Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer DiagnosisHong Li, Chi-Ling Chiang, Kwang Joo Kwak, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.
Journal of the National Cancer Institute|May 17, 2023
Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppressionJason V Evans, Shankar Suman, Mounika Uttam L Goruganthu, et al.
Pageof 66

Showing results (631-640 of 651) with videos related to

Sort By:
Pageof 66
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLCCeline Mascaux, Triparna Sen, Montse Sanchez-Cespedes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Medicine|October 10, 2023
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Cancer Medicine|July 28, 2025
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based TherapiesMingjia Li, Po-Lan Su, Songzhu Zhao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 26, 2025
Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer DiagnosisHong Li, Chi-Ling Chiang, Kwang Joo Kwak, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.
Journal of the National Cancer Institute|May 17, 2023
Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppressionJason V Evans, Shankar Suman, Mounika Uttam L Goruganthu, et al.
Pageof 66